HP184 in Chronic Spinal Cord Injury Subjects

Completed · Phase 2

Conditions studied: Spinal Cord Injury

In brief

The purpose of this study is to determine whether HP184 is effective in the treatment of chronic spinal cord injury (CSCI).

Key facts

Study ID

NCT00093275

Run by

Sanofi

People needed

262

Starts

2004-10-01

Expected to finish

2005-12-01

Last updated by the study team

2008-08-21

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male and female subjects with incomplete (traumatic), chronic (defined as 18 months or more post spinal cord injury) SCI aged 18 to 65 years
• CSCI must be categorized in classes C or D in the ASIA impairment scale. (C = Incomplete impairment with motor function preserved below the neurological level, and more than half of key muscles below the neurological level have a muscle grade less than 3. D = Incomplete impairment with motor function preserved below the neurological level, and at least half of key muscles below the neurological level have a muscle grade more than or equal to 3).
• The level of the SCI must be between C4 and T10 (neurological)
• Subject has a measurable range of motion at the hips, knees and ankles and possesses potential propulsive activity (i.e. no functional contractures)
• Female subjects of childbearing potential (those who are not surgically sterile or who are less than 2 years postmenopausal) must be using two forms of birth control, including a primary and a secondary form and have a negative pregnancy test immediately prior to treatment. Primary forms of contraception include: tubal ligation, partner's vasectomy, intrauterine devices, birth control pills, and topical/injectable/implantable/insertable hormonal birth control products. Secondary forms of contraception include diaphragms, latex condoms and cervical caps; each must be used with a spermicide.

You may not qualify if…

• Any clinical evidence of recent fracture(s) within the last six months prior to study start.
• Any history of Multiple Sclerosis or peripheral demyelinating disease or neuromuscular disorder.
• Heart rate of less than 38 or greater than 100
• Ashworth spasticity score of 0/4 or 4/4 at the hip or knee.
• Subject whose medical condition requires mechanical ventilation.
• Lower motor neuron injury, such as those with conus medullaris or cauda equina injuries.
• Subject with lower extremity amputation or proximal femorectomy.
• Subject with pressure ulcers stages 3 and 4.
• Subject medically or mentally unstable in judgment of Investigator.
• Subject on tricyclic antidepressants such as nortriptyline, amitriptyline and imipramine.
• Subject with ASIA motor score of greater than or equal to 92.
• Subject with ASIA sensory score of greater than or equal to 200.
• Subject with history of seizure within 2 years prior to study start.
• Subjects who have participated in a clinical trial involving investigational medication within 30 days prior to administration of HP184 or placebo.
• Female subjects with positive urine pregnancy test.
• Female subjects who are breast feeding.

Where it is running

• Sanofi-Aventis Administrative Office — Bridgewater, New Jersey, United States
• sanofi-aventis administrative Australia & New-Zealand administrative office — Macquarie Park, New South Wales, Australia
• Sanofi-Aventis Administrative Office — Berlin, Germany
• Sanofi-Aventis Administrative Office — Mumbai, India
• Sanofi-Aventis Administrative Office — Guildford Surrey, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.